Furosemide as a Probe Molecule for the Treatment of Neuroinflammation in Alzheimer’s Disease
- 23 November 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 11 (24) , 4152-4168
Abstract
The accumulation and deposition of β-amyloid (Aβ) is one postulated cause of Alzheimer’s disease (AD). In addition to its direct toxicity on neurons, Aβ may induce neuroinflammation through the concomitant activation of microglia. Emerging evidence suggests that microglia-mediated neuroinflammation plays an important role in the pathogenesis of AD. As brain macrophages, microglia engulf misfolded-Aβ by phagocytosis. However, the accumulated toxic Aβ may paradoxically “hyper-activate” microglia into a neurotoxic proinflammatory and less phagocytotic phenotype, contributing to neuronal death. This study reports that the known drug furosemide is a potential probe molecule for reducing AD-neuroinflammation. Our data demonstrate that furosemide inhibits the secretion of proinflammatory TNF-α, IL-6, and nitric oxide; downregulates the mRNA level of Cd86 and the protein expression of COX-2, iNOS; promotes phagocytic activity; and enhances the expression of anti-inflammatory IL-1RA and arginase. Our mechanism of action studies further demonstrate that furosemide reduces LPS-induced upregulation of endoplasmic reticulum (ER) stress marker genes, including Grp78, Atf4, Chop, tXbp1, and sXbp1. These data support the observation that furosemide is a known drug with the capacity to downregulate the proinflammatory microglial M1 phenotype and upregulate the anti-inflammatory M2 phenotype, a potentially powerful and beneficial pharmacologic effect for inflammatory diseases such as AD.Keywords
Funding Information
- Canada Research Chairs
This publication has 51 references indexed in Scilit:
- Deciphering Resting Microglial Morphology and Process Motility from a Synaptic ProspectFrontiers in Integrative Neuroscience, 2016
- Alzheimer's diseaseBMJ, 2009
- Amyloid β-peptide is produced by cultured cells during normal metabolism: A repriseJournal of Alzheimer’s Disease, 2006
- Neural Immunity: Friend or Foe?Journal of NeuroVirology, 2002
- Clinical features of Alzheimer's diseaseEuropean Archives of Psychiatry and Clinical Neuroscience, 1999
- Amyloid deposition as the central event in the aetiology of Alzheimer's diseaseTrends in Pharmacological Sciences, 1991
- Psychiatric Phenomena in Alzheimer's Disease. I: Disorders of Thought ContentThe British Journal of Psychiatry, 1990
- Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides.Proceedings of the National Academy of Sciences, 1987
- Amyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer LocusScience, 1987
- The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptorNature, 1987